10-Q · May 6, 2026
DiaMedica Therapeutics posted a net loss of $10 million for Q1 2026, an increase from $7.7 million in the prior year, and continues to operate without revenue generation. R&D expenses surged to $8 million as the company…
Earnings analysis · 10-Q
DMAC earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
DiaMedica reported a Q2 2026 diluted loss of $0.19 per share, beating the $0.20 consensus loss estimate but deteriorating from the $0.18 loss in the prior-year quarter. Revenue, margins, free cash flow and segment data…
Read full summary
DiaMedica reported a Q2 2026 diluted loss of $0.19 per share, beating the $0.20 consensus loss estimate but deteriorating from the $0.18 loss in the prior-year quarter. Revenue, margins, free cash flow and segment data were not disclosed in the supplied filing text. Clinical progress was encouraging, with significant blood-pressure reductions in 15 preeclampsia patients and ReMEDy2 enrollment above 85% of its 200-participant interim-analysis threshold, but the company remains dependent on finite cash resources of $43.5 million expected to fund operations through 2027.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.19
What stood out
-
EPS beat consensus
Diluted EPS was a loss of $0.19, modestly better than the $0.20 consensus loss estimate but worse than the $0.18 loss reported in Q2 2025.
-
Positive preeclampsia data
Blood-pressure reductions were statistically significant in 15 preeclampsia patients, providing a positive clinical readout for the company’s development program.
-
Stroke trial nears interim analysis
ReMEDy2 enrollment exceeded 85% of the 200-participant interim-analysis threshold, indicating the stroke trial is approaching its planned interim analysis.
-
Funding runway through 2027
Management expects $43.5 million of cash, cash equivalents and short-term investments to fund planned studies and operations through 2027.
-
Effective disclosure controls
The company concluded that disclosure controls were effective as of June 30, 2026, and reported no material change in internal control during the three months ended June 30, 2026.
What to watch
-
Finite funding runway
The company continues to fund clinical development without reported revenue, and management’s stated $43.5 million funding pool is expected to support operations only through 2027, increasing future financing risk.
-
Clinical trial execution risk
ReMEDy2 enrollment has surpassed 85% of its 200-participant interim-analysis threshold, but the program still faces clinical, regulatory and execution risk before producing definitive results.
-
Prior 10-K risks remain
The filing states that there were no material changes to the risk factors disclosed in the 10-K for the fiscal year ended December 31, 2025; those risks remain applicable and could materially affect results.
Management's outlook
No formal numeric revenue or EPS guidance was provided. Management stated that cash, cash equivalents and short-term investments of $43.5 million are expected to fund planned studies and operations through 2027; R&D expenses are expected to increase moderately while G&A expenses are expected to remain relatively steady.
Earlier filings 4
10-K · March 30, 2026
DiaMedica is a clinical-stage biopharmaceutical company advancing DM199 (recombinant KLK1) in preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS). The 10-K highlights positive Phase 2…
10-Q · August 12, 2025
DiaMedica reported a Q2 net loss of $7.699 million (EPS -$0.18) versus a loss of $5.119 million (EPS -$0.13) in Q2 2024; operating loss widened to $8.007 million from $5.638 million a year ago. The company remains a…
10-K · March 17, 2025
DiaMedica is a clinical-stage biopharmaceutical company focused on DM199 for acute ischemic stroke (AIS) and preeclampsia (PE). The company emphasizes its recombinant rhKLK1 as the first and only rhKLK1 in global…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.